Compare WPRT & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | LIXT |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 25.4M |
| IPO Year | 1995 | N/A |
| Metric | WPRT | LIXT |
|---|---|---|
| Price | $2.13 | $3.48 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 112.3K | 88.8K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $290,323,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 140.81 | N/A |
| 52 Week Low | $1.54 | $0.64 |
| 52 Week High | $4.77 | $6.26 |
| Indicator | WPRT | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 49.25 |
| Support Level | $2.05 | $3.04 |
| Resistance Level | $2.31 | $3.53 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 48.00 | 67.85 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three operating segments; the Original Equipment Manufacturers segment-design, manufacture, and sell alternative fuel systems, components and electronics, and related engineering services, to OEMs that serve light-duty, medium-duty, and heavy-duty customers, the Independent Aftermarket segment includes IAM products, conversion kits, and components allow for the conversion of vehicles after being sold to the end-user through a network of dealers and installers, and Corporate includes public company activities, corporate oversight, financing and capital allocation.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.